A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Immunogenicity of STSP-0902 in Healthy Subjects
Latest Information Update: 28 Aug 2024
Price :
$35 *
At a glance
- Drugs STSP 0902 (Primary)
- Indications Asthenozoospermia; Oligospermia
- Focus Adverse reactions
- Sponsors Staidson Beijing BioPharmaceuticals
- 27 Aug 2024 New trial record
- 26 Aug 2024 Status changed from not yet recruiting to recruiting.